The EndoZyme® II assay, available since May 2017, is the enhanced second generation of EndoZyme® – an endpoint fluorescent microplate assay intended for in vitro quantitative determination of endotoxin in pharmaceuticals and biological substances as well as for medical device testing.
The endotoxin-specificity of EndoZyme® II eliminates all false-positive and elevated results seen by ß-glucan reactions in the LAL test. Adding the excellent sensitivity, ease-of-use and very high lot-to-lot consistency, the LAL alternative EndoZyme® II is a representative of modern recombinant methods, moving away from the animal source which for decades has been the horseshoe crab.
Being a homogeneous assay without solid phase, EndoZyme® II is particularly suited for non-complex samples and buffer conditions, such as water testing. For complex sample matrices, EndoLISA® is recommended.
All reagents needed for running EndoZyme® II are included in the kit:
Specifications and advantages:
Highly sensitive rFC endotoxin detection assay with measurement range 0.005 – 50 EU/ml
No false-positive glucan reaction due to endotoxin-specific recombinant technology
Excellent reliability and lot-to-lot reproducibility
All needed reagents included in the kit
Flexible testing format: microtiter plate
No animal material, therefore saving the diminishing horseshoe crab population
Additional material needed:
Fluorescence microplate reader
Lab shaker/vortex mixer
Endotoxin-free disposables and glassware